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Paediatric diseasen clinical manifestation in childrenwith mitochondrial disease and other types of
inborn errors of metabolism. We characterised clinical symptoms, prognosis, respiratory chain function and
performed extensive genetic analysis of 25 Swedish children suffering from Leigh syndrome with the aim to
obtain insights into the molecular pathophysiology and to provide a rationale for genetic counselling. We
reviewed the clinical history of all patients and used muscle biopsies in order to perform molecular,
biochemical and genetic investigations, including sequencing the entire mitochondrial DNA (mtDNA), the
mitochondrial DNA polymerase (POLGA) gene and the surfeit locus protein 1 (SURF1) gene. Respiratory chain
enzyme activity measurements identiﬁed ﬁve patients with isolated complex I deﬁciency and ﬁve with
combined enzyme deﬁciencies. No patient presented with isolated complex IV deﬁciency. Seven patients had
a decreased ATP production rate. Extensive sequence analysis identiﬁed eight patients with pathogenic
mtDNA mutations and one patient with mutations in POLGA. Mutations of mtDNA are a common cause of LS
and mtDNA analysis should always be included in the diagnosis of LS patients, whereas SURF1 mutations are
not a common cause of LS in Sweden. Unexpectedly, age of onset, clinical symptoms and prognosis did not
reveal any clear differences in LS patients with mtDNA or nuclear DNA mutations.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Leigh syndrome (LS) or subacute necrotising encephalopathy
(OMIM #256000) is a progressive neurodegenerative disorder of
infancy and early childhood [1]. Focal, bilateral lesions in one or more
areas of the central nervous system, including the brainstem,
thalamus, basal ganglia, cerebellum or spinal cord are observed at
autopsy [2]. The lesions typically consist of areas of demyelinization,
gliosis, necrosis, spongiosis and capillary proliferation. Deﬁnite
diagnosis of LS is based on neuropathology, but imaging techniques
can be used to support the diagnosis. Typical ﬁndings include bilateral
hypodensities in the basal ganglia or brainstem on computed
tomography (CT) or hyperintense lesions on T2-weighted magnetic
resonance imaging (MRI) [3]. Patients with LS have a wide spectrumondrial ATP production rate;
ubunit of mitochondrial DNA
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ll rights reserved.of clinical presentations including hypotonia, ataxia, dystonia,
epilepsy, respiratory abnormalities, nystagmus, optic atrophy and
ophthalmoplegia. Failure to thrive or developmental retardation is
often an early but unspeciﬁc sign of the disease. Stepwise deteriora-
tion with some recovery of skills between episodes of regression is
common. The severe neurological symptoms are caused by a range of
different biochemical and molecular defects interfering with cellular
energy production in affected brain regions.
One of the most common causes of LS is a disturbance of the
mitochondrial oxidative phosphorylation (OXPHOS) system. The
OXPHOS system comprises ﬁve enzyme complexes, where an electron
transport chain (complexes I to IV) creates a proton gradient across
the mitochondrial inner membrane, which, in turn, is used by ATP
synthase (complex V) to generate ATP. This process is under dual
genetic control, because key subunits of complexes I, III, IV and V are
encoded by mtDNA. Mitochondrial diseases in children encompass a
wide spectrum of clinical phenotypes and LS is a common disease
entity with an estimated minimal incidence of 1 in 34,000 preschool
Swedish children (b6 years) [4]. Molecular defects have been
identiﬁed in both nuclear and mitochondrial encoded respiratory
chain (RC) subunits in children with LS and the inheritance can be
maternal, X-linked or autosomal recessive. Mutations in nuclear genes
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in affected patients. For instance, mutations in the complex IV
assembly factor, surfeit locus protein 1 (SURF1), have been shown to
be a common cause of LS [5,6]. Additionally, mutations in genes
encoding subunits for pyruvate dehydrogenase, such as the X
chromosome-linked E1α subunit gene, have been associated with
LS. The aetiology of a large proportion of LS cases is still unknown,
despite substantial progress in genetic characterisation. A study of 67
patients with deﬁnite or probable LS identiﬁed the underlying
biochemical or molecular defect in ∼80% of deﬁnitive Leigh cases,
and in ∼40% of probable cases [7]. A second study involving 66 LS
patients identiﬁed the biochemical or molecular cause in only ∼50% of
the patients [8]. We performed a study of 25 Swedish children
diagnosed with LS in order to characterise the clinical symptoms,
prognosis, respiratory chain function and genetic aetiology and to
provide a rationale for genetic counselling for affected families. We
assessed the importance of mtDNA mutations as a cause for LS by
performing an extensive analysis of mtDNA in all cases. We report
here that mtDNA mutations are a frequent cause of LS. Unexpectedly,
we ﬁnd that nuclear and mtDNA mutations cause similar LS disease
phenotypes associated with early onset and poor prognosis. We found
no nuclear DNA mutations affecting the SURF1 gene in this cohort of
Swedish LS patients.
2. Materials and methods
All 25 patients were primarily investigated and diagnosed with LS,
by their local paediatrician between the years 1989 and 2006 and then
referred to the Centre for Inherited Metabolic Diseases at Karolinska
University Hospital in Huddinge, Sweden. Patients 15 and 21 were
referred post mortem. All patients were born in central Sweden, with
seven children having at least one parent of non-Swedish origin.
Patients 14, 15, 20 and 21 were diagnosed at autopsy. Patients 23 and
24 had typical features on CT. The remaining 19 patients had typical
ﬁndings on MRI. One of us (KN) examined 15 of the patients at
different stages of their disease and reviewed the medical records
from all 25 patients. Patients 7 and 11 have been reported previously
[9]. The study was approved by the regional ethics committee in
Stockholm, Sweden.
2.1. Laboratory investigations
Organic acids in urinewere analyzed by using gas chromatography
combined with mass spectrometry [10]. Lactate levels were measured
in blood and cerebrospinal ﬂuid (CSF) by laboratories at the local
hospitals.
2.2. Biochemical measurements
All patients, except 15 and 21, were subjected to a percutaneous
muscle biopsy using a conchotome as described previously [11].
Patients 1–4, 6, 8, 10–13, 18–20, 22–24 were investigated between
1991 and 2000 to determine mitochondrial adenosine triphosphate
(ATP) production rate (MAPR), RC enzyme activities, glutamate
dehydrogenase activities and citrate synthase activities, as described
previously [12,13]. The results from these patients were compared
with a control group aged one month to ﬁve years (n=12). Patients
5, 7, 9, 14, 16, 17 and 25 were investigated between 2001 and 2006
with an improved set of the same methods [11], which included the
determination of complex I activity (NADH-coenzyme Q reductase),
except in patients 14 and 16. The results were compared with a
control group aged two months to ﬁve years (n=11). Patient results
diverging more than ±2 standard deviations from the control group
were considered pathological. Pyruvate dehydrogenase complex
(PDHc) activity was determined with a radioisotope method as
described previously [14].2.3. Morphological analyses
Morphological examinations of skeletal muscle, including electron
microscopy and enzyme histochemical staining, were performed as
described previously [15].
2.4. DNA sequence analysis
Both DNA strands of all samples were sequenced using BigDye v3.1
terminator technology (Applied Biosystems), run on a 3130XL
sequencer (Applied Biosystems) and aligned to the appropriate
reference sequences using SeqScape software v2.5 (Applied Biosys-
tems). All primers used in PCR ampliﬁcations for sequencing were
M13-tagged for ease of sequencing.
The complete mitochondrial genome was ampliﬁed from all
patients except 7, 11, 16 and 19 who had known pathogenic
mutations, and patients 15 and 23, being monozygotic twins of
patients 14 and 24, respectively. We used 28 overlapping primer
pairs (essentially as in [16] and shown in Supplemental material),
and the resulting PCR products were sequenced and aligned to the
revised Cambridge reference sequence (AC_000021.2). Sequence
changes were further compared to MitoMap [17] and the Human
Mitochondrial Genome Database (mtDB) [18] (both accessed June
2007). Mutations were also compared to the mtDNA database from
MIGENIX Corp., San Diego, California, USA (Elson J. University of
Newcastle, UK, personal communication).
The gene encoding the surfeit locus protein 1 (SURF1) was
sequenced in all patients except the ones, in which we had found
known pathogenic mtDNA mutations (described in [5] and see
Supplemental material). The catalytic subunit of mitochondrial DNA
polymerase (POLGA) was sequenced in patients 7, 11, 14, 15, 16, 17,
19 and 20 (described previously in [19] and shown in Supplemental
material).
2.5. Quantiﬁcation of mtDNA mutation levels
Mutation levels were quantiﬁed by last-hot-cycle RFLP ana-
lyses, where PCR ampliﬁcations were labelled with [α32P] dCTP
(GE Healthcare) in the last cycle, followed by digestion with an
appropriate endonuclease (see Supplemental material) and
separation by electrophoresis in non-denaturing polyacrylamide
gels. Quantiﬁcation was performed by phosphor-imaging (BioRad),




Patients were diagnosed with LS based on the following,
previously used, criteria: (i) a progressive neurological disease with
basal ganglia and/or brainstem involvement and either (ii) character-
istic neuropathological changes at autopsy or (iii) characteristic
ﬁndings on cerebral imaging, which had to include symmetrical
changes in the basal ganglia and/or brainstem [3]. We identiﬁed 25
children with LS, 14 boys and 11 girls, from our database of 1285
patients investigated because of suspected mitochondrial disease.
Two pairs of monozygotic twins were among the patients but no other
siblings were affected.
Despite the common neurological criteria used in this study, the
cohort showed a wide variety of clinical presentations (Table 1). For
instance, 16 children (64%) developed seizures, occasionally progres-
sing to drug-resistant epilepsy. Amajority of the patients had failure to
thrive/poor feeding. More than half of the patients suffered from
gastrointestinal problems, such as episodic vomiting or signs of
gastrointestinal dysmotility. Eight patients (32%) showed signs of
Table 1
Summary of clinical ﬁndings












1 M Birth 9 y + + + − + − +
2 F 6 mo 7 y 4 mo + + + − + + −
3 F Birth + − − − − + −
4 M 3 mo 4 y 11 mo + + − + − − −
5 F 3 mo 1 y + + − − + − −
6 M 7 y − − + − + − −
7 F 3 mo + + + − + +m −
8 F Birth + + + + − + −
9 M 21 mo − + − + + − −
10 F 18 mo 9 y 10 mo + + + + + + −
11 F Birth + + + + + + −
12 F 5 mo + + − + + − −
13 M 3 mo 6 y + − + − + +m −
14⁎ M 5 mo 5 mo − − + − + + −
15⁎ M 5 mo 5 mo − − + − + + −
16 M 5 mo 3 y + + − − + + −
17 M 3 mo 13 mo + + − + − +m −
18 M Birth 20 mo + + + − − + −
19 F 2 mo 1 y + + − − − − −
20 M 4 mo 1 y + + − − + − −
21 F Birth 9 mo + + − − + + −
22 F 2 y 14 y 10 mo + + + + − +m +
23⁎ M Birth 9 y 7 mo + + − − + + −
24⁎ M Birth 14 y 10 mo + + − − + + +
25 M 2 y − − − − + − −
M = male, F = female, mo = months, y = years, + = pathological ﬁnding, −= normal ﬁnding, m = myoclonus, ND = not determined, ⁎= monozygotic twins. Abnormal eye
motility includes strabism, ophtalmoplegia and nystagmus. Gastrointestinal problems include episodic vomiting and signs of gastrointestinal dysmotility, such as episodic
abdominal pain, alternating diarrhoea and constipation.
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hyperammonemia, while patient 22 showed transient signs of hepatic
dysfunction assumed to be due to medication with valproic acid. The
other six patients had a slight to moderate increase in serum
transaminases.
3.2. Lactate and organic acids in urine
Lactate levels were normal (b2.3 mmol/l) in four patients, while
the remaining 21 patients (84%) showed various degrees of increased
lactate levels in blood and/or CSF (Table 2). Ten patients (40%)
excreted elevated levels of Krebs cycle intermediates, mostly fumarate
and malate, in the urine. Three boys, patients 1, 23 and 24, excreted
increased levels of 3-methylglutaconic acid. They all presented with
developmental retardation, hypotonia, extrapyramidal symptoms,
hearing loss, feeding difﬁculties and hepatic disorder. Patient 12
excreted methylmalonic acid without responding to treatment with
megadoses of vitamin B12. Patient 2 excreted high amounts of α-
ketoglutaric acid.
3.3. Muscle morphology
We performed muscle biopsies in 23 patients and 15 of these had
normal muscle morphology. Five patients had slightly increased lipid
accumulation and three patients had ﬁbre size variation with one
patient having a decreased ﬁbre size. None of the subjects had
ragged-red ﬁbres or cytochrome c oxidase deﬁciency as determined
by COX/SDH double staining (data not shown).
3.4. Biochemistry
Ten patients (43%) had deﬁciencies in RC enzyme activities. Five
patients (22%) presented with an isolated complex I deﬁciency and
ﬁve had combined enzyme deﬁciencies. No patient showed an
isolated complex II or complex IV deﬁciency. MAPR was normal in14 patients (60%), while seven patients had decreased and two
patients increased MAPR (Table 2).
Deﬁcient PDHc activity has been proposed to be involved in
approximately 10% of LS patients. Three patients (patients 2, 14 and
21) were subjected to analysis of PDHc and had normal activities. In a
further 6 patients (5, 7, 9, 16, 17 and 25; investigated between 2001
and 2006) a PDHc deﬁciency could be excluded because MAPR in the
presence of pyruvate+malate was normal. Prior to 2001 our method
for determination of mitochondrial ATP production was less sensitive
to assess pyruvate oxidation and it is therefore possible that PDHc
deﬁciency may exist in this group.
3.5. Sequence analysis
In order to determine the underlying genetic cause for LS in these
patients, we performed extensive mtDNA sequence analysis on 19
patients (see Materials and methods). We identiﬁed 213 changes from
the Cambridge reference sequence, of which most have been reported
to be polymorphisms according to the MitoMap [17] or mtDB human
[18] databases. We identiﬁed 11 novel mutations considered not to be
pathogenic. Eight patients (32%) carried six differentmtDNAmutations,
previously reported to cause LS (Table 3). Several mutations were
quantiﬁed in a variety of tissues and, if available, maternal relatives, in
order to suggest causality (see Table 2 and Supplemental Fig. 1).
Patient 22 carried three novel mutations at positions 8920, 10,861
and 14,473. The latter two are silent changes, whereas them.8920GNA
transition results in a glycine to serine substitution at position 132 in
ATPase6. Additionally, the patient carried the previously described
m.9957TNCmutation in COX III [20,44]. Both, the m.8920GNA and the
m.9957TNCmutations were present at high levels in samples from the
patient and three healthy maternal relatives (Fig. 2B and C). We thus
do not expect these mutations to be pathogenic.
We sequenced the POLGA locus in 6 of the 8 patients with
suspected hepatic involvement (Table 2; Patient 14 was not included























− + + + − + + + + − −
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− − − − − + + − − + −
+ − − + − + − − − − −
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(patient 17) to be a compound heterozygote for the POLGA
substitutions W748S [21] and R852C [22]. This patient also carried
the recently described G11D substitution linked to the R852C
substitution [24].Table 2
Summary of biochemical and genetic ﬁndings
Patient P-lactate CSF-lactate Organic acids RC enzyme deﬁciency MAPR Tissue
1 ↑ ↑↑ ++ I+III and II+III − Musc
2 ↑↑ ↑ ++ − ↓ Musc
3 ↑↑ ND + I+III − Fibrob
4 ↑↑ ND + − − Fibrob
5 ↑↑ − + I+III − Musc
6 − ↑ − − − Musc
7 ↑↑ ↑↑ + I and I+III − Musc
8 − ND − − ↓ Fibrob
9 ↑ − − − − Musc
10 ↑ − − − − Fibrob
11 − ↑ − I+III ↑ Musc
12 ↑ ↑ + I+III − Musc
13 ↑↑ ↑ − − − Musc
14⁎ ↑ ↑↑ + I+III ↓ Musc
15⁎ ↑ ↑ + ND ND ND
16 ↑↑ ND + I+III and II+III ↓ Musc
17 − − − − − Musc
18 ↑↑ − − − − Musc
19 ↑↑ ↑ + − − Musc
20 ↑ ↑ ++ − ↓ Musc
21 − − − ND ND Fibrob
22 ↑ − + − ↑ Fibrob
23⁎ ↑ ND + I+III and II+III and IV ↓ ND
24⁎ ↑↑ ND + I+III and II+III and IV ↓ Fibrob
25 − − − − − Fibrob
P = plasma, CSF = cerebrospinal ﬂuid, ↑ = increased lactate 2.3–5.0 mmol/l (ref. in pla
ﬁnding, ++ = highly pathological secretion,−= normal ﬁnding, ND = not determined, ⁎
enzyme activities of NADH-coenzyme Q reductase, NADH-cytochrome c reductase, su
mitochondrial ATP production rate, ↑ = increased MAPR, ↓ = decreased MAPR.Although there were no cases with complex IV deﬁciency in the 25
LS patients presented here, we nevertheless sequenced the SURF1
gene from all patients (n=17) that did not have pathogenic mtDNA or
POLGA mutations. No pathogenic SURF1 mutations were found in
these cases.sequenced mtDNA Mutation load POLGA
le − − −
le − − −
lasts − − ND
lasts − − ND
le − − ND
le m.10197GNA 31% ﬁbroblast, 50% muscle ND
le m.10191TNC Ref. [9] ND
lasts − − −
le − − ND
lasts − − ND
le m.14487TNC Ref. [9] ND
le − − ND
le − − ND
le m.14487TNC Homoplasmic ND
ND − ND
le m.8993TNG 96% blood, 86% ﬁbroblast,
95% muscle
ND
le − − W748S/R852C
le − − ND
le m.8993TNC ND ND
le m.14459GNA 99% ﬁbroblasts ND
lasts − − ND
lasts m.8920GNA; m.9957TNC Homoplasmic −
ND − ND
lasts − − −
lasts − − ND
sma and CSF b 2.3 mmol/l), ↑↑ = increased lactate N5.0 mmol/l, + = pathological
= monozygotic twins. I, I+III, II+III, IV refer to the analyses of the respiratory chain
ccinate-cytochrome c reductase and cytochrome c oxidase, respectively. MAPR =
Table 3
Summary of novel and previously reported polymorphisms and pathogenic mtDNA
mutations (bold)
Mutation Gene Substitution Patient Comments and reference
m.291insA D-loop – 17 Novel, delA reported
m.896ANG 12S rRNA – 2 Novel
m.2709ANG 16S rRNA – 5 Novel
m.6977ANG COXI Silent 10 Novel
m.8519GNA⁎ ATPase8 E52K 9 Homoplasmic in mother
and patient, [40]
m.8920GNA ATPase6 G132S 22 Novel, maternal relatives
and patient homoplasmic.
m.8993TNC ATPase6 L156P 19 [41]
m.8993TNG ATPase6 L156R 16 [42]
m.9804GNA COXIII A200T 21 Associated with LHON [43]
m.9957TNC⁎ COXIII F251L 22 [20,44]
m.10191TNC# ND3 S45P 7 [45]
m.10197GNA ND3 A47T 6 [26,27]
m.10410TNA mt-tRNAArg – 13 Novel, T10410C reported
m.10496ANG ND4L Silent 25 Novel
m.10861TNC ND4 Silent 22 Novel
m.13148CNT ND5 P271L 5 Novel
m.13528ANG ND5 T291A 8 Not conserved —
LHON-like phenotype, [46]
m.14357ANG ND6 V106A 14 Novel
m.14459GNA ND6 A72V 20 [47,48]
m.14487TNC# ND6 M63V 11, 14 [28,29]
m.14473ANG ND6 Silent 22 Novel
# = determined by CSGE, conﬁrmed by RFLP, ⁎ = reported as polymorphism in this
study.
Fig. 1. Similar disease onset (A) and prognosis (B) in patients with mtDNA mutations
(lines) or nuclear mutations (dots). Combined data is shown as a solid graph. Age is
presented in years, data presented as numbers of total.
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of disease before or at the age of two years and 20 patients (80%) had
onset before six months of age (Fig. 1A). In a few cases onset was
dramatic with premature birth, asphyxia at birth or severe hepatic
dysfunction. However, more often the patients presented with subtle
and unspeciﬁc symptoms such as failure to thrive or slightly retarded
motor development. Many of these children later developed episodes
of sudden deterioration, often in relation to an infection. Median age
of onset in the entire cohort was three months, with the group
carrying pathogenic mtDNA mutations not differing from the
remaining patients. The mean age of disease onset was at 8.7 months
for the entire cohort, with the mtDNA mutation group presenting at
13.5 months, in comparison to 6.5 months for the remaining patients.
However, this difference in mean age of onset was completely
explained by the late onset of disease of patient 6 in the mtDNA
mutation group. This patient was referred to a physiotherapist at the
age of seven years because of mild motor problems involving balance
and coordination. At eight years of age he developed dysartria.
Initially, there was a slight progress but at 14 years of age the clinical
situation is stable. We identiﬁed moderate levels of the m.10197GNA
mutation in ﬁbroblasts and skeletal muscle samples from this patient,
31 and 50% mutation load, respectively (Fig. 2).
Seventeen patients are no longer alive (68%) and of those ten
patients died before the age of ﬁve years (40%), and the remaining
seven patients before 15 years of age (Fig. 1B). The mean age of death
for the patients with mtDNA mutations was 14 months whereas the
remaining group had a mean age of death of 78.3 months (mean value
of the entire cohort was 58 months). Of the 20 patients with onset
before six months of age, 15 (75%) are no longer living (Table 1).
Disease progression differed greatly among the cohort, ranging from
only several weeks between initial symptoms and death (patients 14
and 15) to several years (e.g. patients 1 and 24). The average time
between initial symptoms and death was close to 10 months (n=5; S.
D.=12.6) within the group with pathological mtDNA mutations and
74.3 months (n=12; S.D.=54.4) for the remaining patients.
Remarkably, the oldest patient in our material is a 22 year old female
(patient 8), who had onset of disease at birthmanifested as hypotonia,
developmental retardation, epilepsy and poor feeding.4. Discussion
We demonstrate here that pathogenic mutations of mtDNA are a
frequent cause of LS in children. Eight of 25 investigated patients
(32%) carried pathogenic mtDNA mutations and one patient was a
compound heterozygote for pathogenic POLGA mutations. The
extensive analysis of mtDNA, with more than 6.4×105 bases
sequenced, makes it very likely that the remaining 16 patients have
yet undiagnosed nuclear mutations. The diagnosis of LS is in majority
of the patients based on the combination of typically localized
ﬁndings on neuroimaging and clinical symptoms derived from these
lesions. Nine of the 23 investigated patients showed normal
mitochondrial function, a common diagnostic problem for a subset
of patients with suspected mitochondrial disorders. In three of these
patients we could detect a pathogenic mutation in mtDNA or in
POLGA. The majority of the remaining six patients had very typical
clinical features combined with biochemical abnormalities such as
increased levels of lactate or abnormal excretion of organic acids,
making it very likely that they are/were suffering from a respiratory
chain disorder. However, a few children remainwith a more uncertain
diagnosis and even if the principal aetiology behind LS is a primary
respiratory chain disorder, it can in exceptional cases also be caused by
other rare neurological or neurometabolic disorders. Excluding all
potential aetiologies was not possible in this retrospective study.
One patient (patient 17) was compound heterozygous for three
previously describedmutations in POLGA. Patients that are compound
Fig. 2. Last-hot-cycle RFLP analysis of various mtDNA changes. (A) The mutation levels
of the m.10197GNA (using the restriction endonuclease Bcc I) were determined in
ﬁbroblasts (31%) and muscle (50%) from patient 6. (B) The novel m.8920GNAmutation
(using the restriction endonuclease Tat I) and (C) the m.9957TNC mutation (using the
restriction endonuclease Mbo II) were both at or close to homoplasmic levels in
ﬁbroblasts from patient 22 aswell as in blood samples from thematernal uncle (1), aunt
(2) and grandmother (3). All mutation levels are calculated as % of the wildtype
fragment ±2%. -ve indicates ampliﬁcation without DNA.
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develop Alper's syndrome, whereas patients that are compound
heterozygous for W748S and either Q497H, L304R, or A467T develop
spino-cerebellar ataxia and epilepsy [23]. Recently, a patient carrying
the W748S mutation in trans with both, the R852C and G11D, was
reportedwith ataxia, neuropathy and failure to thrive [24]. The patient
presented here appeared hypotonic with retardedmotor development
at three months of age and developed epilepsy with intractable
myoclonic seizures at six months of age. His disease state gradually
progressed andhedied at age13months. A subtle hepatic involvement
was noted once, with slightly increased transaminases and possible
enlarged liver. The patient did not develop microcephaly and an MRI
scan at eight months of age showed high signalling lesions in
subcortical areas. A follow-up scan at one year of age revealed a
progressive decline with high signalling areas of thalamus bilaterally
and widespread changes of the white matter, not typically observed
in Alper's syndrome (OMIM #203700). The patient had signs of
brainstem dysfunction and thus was included in this cohort of LS
patients, although presenting with an Alper's-like phenotype. The
G11D mutation has recently been found in trans with the R852C
mutation, in a 15 year-old patient with symptoms compatible with
Alper's syndrome [25]. However, it is not clear yet in what way the
G11D mutation inﬂuences the disease phenotype and progression.
The group of patients with mtDNA mutations did not differ from
the group of patients without demonstratedmutations, with regard to
the clinical phenotype. They all had severe neurological symptoms,reﬂecting injuries of very central parts of the brain, as expected from
the inclusion criteria. Seizures were an equally frequent ﬁnding in
both groups (62.5% and 65%, respectively). Non-neurological symp-
toms were present in both groups.
Three children (patients 6, 9 and 25) presented with less severe
phenotypes and delayed onset of disease. Patient 9 developed an
encephalitis-like disease at the age of 21 months, from which he
partially recovered after several weeks, but still had a coordination
disorder with slight choreatetotic movements. In this patient we
found the m.8519GNA transition mutation, which has previously been
reported in conjunction with MELAS, seizures, autistic behaviour and
developmental delay [17]. However, we found this mutation to be
homoplasmic in both the patient and his mother. Additionally, the
Uppsala mtDNA database reports one sequence with this transition
among its 2704 sequences from healthy subjects [18]. We therefore
propose that this mutation is a rare polymorphism.
Patient 25 presented with a squint at two years of age and
developed painful dystonias in his lower extremities at age four years.
His development was normal. We were unable to identify a genetic
cause in this patient. However, patient 6, who carries them.10197GNA
mutation, was referred to a hospital due tomildmotor problems at the
age of seven years. This mutation in ND3 has recently been described
to cause LS and dystonia [26] or an unspeciﬁed encephalopathy with
basal ganglia lesions [27]. Unlike the previous cases, where high levels
of the m.10197GNA mutation caused a complex I deﬁciency and a
severe clinical phenotype, patient 6 of this study had much lower
mutation levels and amilder clinical phenotype without RC deﬁciency
in skeletal muscle, suggesting that a more gradual threshold might be
associated with this mutation.
We identiﬁed two potentially disease causing mutations in patient
22. The novel m.8920GNA transition leads to a glycine to serine
substitution in ATP6, while the m.9957TNC mutation has been
previously reported in a boy with MELAS [20] and a man with non-
arteritic ischemic optic neuropathy (NAION) [44]. The latter mutation
results in a phenylalanine to leucine substitution in COX III. Neither
the previously described cases, nor patient 22 in this report had
complex IV deﬁciency. Additionally, both of these mutations were
carried at very high (likely homoplasmic) levels in the patient and
three healthy maternal relatives. We therefore suggest that both of
these mutations are rare polymorphisms.
The m.14487TNC mutation in ND6 seems to affect complex I
stability and has previously been reported in LS patients [28,29]. We
identiﬁed the mutation in two unrelated families. Interestingly,
despite the high mutation levels in patients 11 (previously described
[9]) and 14, the clinical and biochemical presentation was very
different. Patients 14 and 15 were twin brothers with sudden
irritability, hypertonus and hypoventilation at ﬁve months of age.
They both deteriorated rapidly and died within three weeks after
admission to a hospital. In contrast, patient 11 has a milder disease
phenotype and is alive at 16 years of age with a severe and slightly
progressive handicap. Patient 14 carried the m.14487TNC mutation at
very high levels (Fig. 2C) and also carried a novel m.14357ANG
transition. This second mutation results in a valine to alanine
substitution at position 106 of ND6 and has previously not been
described. It is possible that this additional mutation may aggravate
the clinical consequences of the m.14487TNC mutation.
Mutations in mitochondrial tRNAs (mt-tRNA) are surprisingly rare
in LS [30,31], despite the observation that mt-tRNA mutations
comprise of the largest group of mtDNA mutations associated with
mitochondrial diseases [32,33]. We found no previously reported mt-
tRNAmutations in the presented cohort of 25 LS patients. However, we
identiﬁed an m.10410TNA transversion in mt-tRNA-Arg, which could
increase the stability of the ACC-stem of mt-tRNA-Arg. No primates
seem to carry an adenine at this position, and a pyrimidine–pyrimidine
interaction is conserved at this position in humans, chimpanzees,
bonobos and gorillas. More diverse primates, however, do carry a
490 K. Naess et al. / Biochimica et Biophysica Acta 1787 (2009) 484–490pyrimidine–purine base pairing at this position, and it is therefore not
clear whether aweak pyrimidine bond at this position is required for a
functional tRNA in humans. We have not quantiﬁed the levels of this
mutation in patient 13, nor in any of his maternal relatives, and it is
therefore not possible to asses whether the mutation load correlates
with the disease. Three of the patients in our cohort had similar
ﬁndings as described previously in patients with a syndrome
consisting of 3-methylglutaconic aciduria, sensorineural deafness,
encephalopathy and Leigh-like syndrome (MEGDEL) [34]. No under-
lying molecular defect has been identiﬁed in MEGDEL patients [34].
Increased levels of lactate in plasma or CSF are often found in LS
patients. However, this is not always the case and cannot be used as a
criterion for LS, as previously suggested [7]. Four of the patients in this
study had normal lactate levels, among them were the boy with
POLGA-mutation and a girl with LS diagnosed at autopsy. We found
abnormal excretion of organic acids in the urine of 15 patients (60%),
suggesting that the measurement of organic acid excretion can be an
important diagnostic tool.
Previous studies have reported that 13% and 26% of LS patients
have a complex IV deﬁciency [7,8]. SURF1 is an assembly factor for
complex IV and mutations of the SURF1 gene are frequently found in
complex IV-deﬁcient LS patients [35–37]. In order to use an in-
dependent method to conﬁrm the absence of complex IV deﬁciency in
our cohort of LS patients, we sequenced the SURF1 gene. We failed to
detect any pathological mutations in SURF1 in 17 analyzed cases,
demonstrating that the prevalence of SURF1 mutations is very low in
Swedish LS patients.
It can be concluded that mtDNA mutations are common among
patients with LS and do not give rise to a milder phenotype. We
therefore suggest that sequencing of the entire mtDNA should be
considered in all patients with LS, irrespective of disease severity.
Mitochondrial dysfunction is found to play an important role in
neuronal death following an acute brain injury, caused by, for
example, stroke, trauma or hypoxia and ischemia after perinatal
events in the newborn brain [38]. These ﬁndings suggest that neurons
with mitochondrial dysfunction are prone to degenerate in response
to exogenous stress. Consistent with this hypothesis, experimental
studies have shown that RC deﬁcient neurons of conditional knockout
mice are hypersensitive to excitotoxic stress and display massive cell
death after induction of epileptic seizures [39]. Therefore, different
neuroprotective treatment strategies that currently are being devel-
oped to treat a variety of neurodegenerative diseases should also be
considered as treatment of mitochondrial disease in a future.
Acknowledgements
The authorswould like to thankDr. J. Elson, University ofNewcastle,
UK for providing access to the MIGENIX Corp. mtDNA database.
This study was supported by the Swedish Research Council,
Swedish Brain Power and Torsten and Ragnar Söderbergs Stiftelse.
Appendix A. Supplementary data
Supplementary data associatedwith this article can be found, in the
online version, at doi:10.1016/j.bbabio.2008.11.014.
References
[1] D. Leigh, J. Neurol. Neurosurg. Psychiatry 14 (1951) 216–221.
[2] J.B. Cavanagh, B.N. Harding, Brain 117 (Pt 6) (1994) 1357–1376.
[3] A.J. Barkovich, W.V. Good, T.K. Koch, B.O. Berg, AJNR Am. J. Neuroradiol. 14 (1993)
1119–1137.
[4] N. Darin, A. Oldfors, A.R. Moslemi, E. Holme, M. Tulinius, Ann. Neurol. 49 (2001)
377–383.
[5] V. Tiranti, K. Hoertnagel, R. Carrozzo, C. Galimberti, M. Munaro, M. Granatiero, L.
Zelante, P. Gasparini, R. Marzella, M. Rocchi, M.P. Bayona-Bafaluy, J.A. Enriquez, G.
Uziel, E. Bertini, C. Dionisi-Vici, B. Franco, T. Meitinger, M. Zeviani, Am. J. Hum.
Genet. 63 (1998) 1609–1621.[6] Z. Zhu, J. Yao, T. Johns, K. Fu, I. De Bie, C. Macmillan, A.P. Cuthbert, R.F. Newbold, J.
Wang, M. Chevrette, G.K. Brown, R.M. Brown, E.A. Shoubridge, Nat. Genet. 20
(1998) 337–343.
[7] S. Rahman, R.B. Blok, H.H. Dahl, D.M. Danks, D.M. Kirby, C.W. Chow, J.
Christodoulou, D.R. Thorburn, Ann. Neurol. 39 (1996) 343–351.
[8] A.A. Morris, J.V. Leonard, G.K. Brown, S.K. Bidouki, L.A. Bindoff, C.E. Woodward,
A.E. Harding, B.D. Lake, B.N. Harding, M.A. Farrell, J.E. Bell, M. Mirakhur, D.M.
Turnbull, Ann. Neurol. 40 (1996) 25–30.
[9] N. Esteitie, R. Hinttala, R. Wibom, H. Nilsson, N. Hance, K. Naess, K.
Tear-Fahnehjelm, U. vonDobeln, K.Majamaa, N.G. Larsson, Ann. Neurol. 58 (2005)
544–552.
[10] J. Alm, L. Hagenfeldt, A. Larsson, Ann. Clin. Biochem. 15 (1978) 245–249.
[11] R. Wibom, L. Hagenfeldt, U. von Dobeln, Anal. Biochem. 311 (2002) 139–151.
[12] U. von Dobeln, R. Wibom, H. Ahlman, I. Nennesmo, H. Nyctelius, E. Hultman, L.
Hagenfeldt, Acta Paediatr. 82 (1993) 1079–1081.
[13] R. Wibom, E. Hultman, Am. J. Physiol. 259 (1990) E204–209.
[14] D. Constantin-Teodosiu, G. Cederblad, E. Hultman, Anal. Biochem. 198 (1991)
347–351.
[15] N.G. Larsson, A. Oldfors, Acta. Physiol. Scand. 171 (2001) 385–393.
[16] R.W. Taylor, G.A. Taylor, S.E. Durham, D.M. Turnbull, Nucleic Acids Res. 29 (2001)
E74–34.
[17] MITOMAP. 2007.
[18] M. Ingman, U. Gyllensten, Nucleic Acids Res. 34 (2006) D749–751.
[19] M. Filosto, M. Mancuso, Y. Nishigaki, J. Pancrudo, Y. Harati, C. Gooch, A. Mankodi, L.
Bayne, E. Bonilla, S. Shanske, M. Hirano, S. DiMauro, Arch. Neurol. 60 (2003)
1279–1284.
[20] G. Manfredi, E.A. Schon, C.T. Moraes, E. Bonilla, G.T. Berry, J.T. Sladky, S. DiMauro,
Neuromuscular Disord. 5 (1995) 391–398.
[21] G. Van Goethem, P. Luoma, M. Rantamaki, A. Al Memar, S. Kaakkola, P. Hackman, R.
Krahe, A. Lofgren, J.J. Martin, P. De Jonghe, A. Suomalainen, B. Udd, C. Van
Broeckhoven, Neurology 63 (2004) 1251–1257.
[22] K.V. Nguyen, F.S. Sharief, S.S. Chan, W.C. Copeland, R.K. Naviaux, J. Hepatol. 45
(2006) 108–116.
[23] K.V. Nguyen, E. Ostergaard, S.H. Ravn, T. Balslev, E.R. Danielsen, A. Vardag, P.J.
McKiernan, G. Gray, R.K. Naviaux, Neurology 65 (2005) 1493–1495.
[24] N. Ashley, A. O'Rourke, C. Smith, S. Adams, V. Gowda, M. Zeviani, G.K. Brown, C.
Fratter, J. Poulton, Hum. Mol. Genet. 17 (2008) 2496–2506.
[25] L.-J.C. Wong, R.K. Naviaux, N. Brunetti-Pierri, Q. Zhang, E.S. Schmitt, C. Truong, M.
Milone, B.H. Cohen, B. Wical, J. Ganesh, A.A. Basinger, B.K. Burton, K. Swoboda, D.L.
Gilbert, A. Vanderver, R.P. Saneto, B. Maranda, C. Arnold, J.E. Abdenur, P.J. Waters,
W.C. Copeland, Hum. Mutat. 1020 (2008) E150–E172.
[26] E. Sarzi, M.D. Brown, S. Lebon, D. Chretien, A. Munnich, A. Rotig, V. Procaccio, Am. J.
Med. Genet. A. 143 (2007) 33–41.
[27] J.H. Chae, J.S. Lee, K.J. Kim, Y.S. Hwang, E. Bonilla, K. Tanji, M. Hirano, Pediatr. Res.
61 (2007) 622–624.
[28] A. Solano, M. Roig, C. Vives-Bauza, J. Hernandez-Pena, E. Garcia-Arumi, A. Playan,
M.J. Lopez-Perez, A.L. Andreu, J. Montoya, Ann. Neurol. 54 (2003) 527–530.
[29] C. Ugalde, R.H. Triepels, M.J. Coenen, L.P. van den Heuvel, R. Smeets, J. Uusimaa, P.
Briones, J. Campistol, K. Majamaa, J.A. Smeitink, L.G. Nijtmans, Ann. Neurol. 54
(2003) 665–669.
[30] R. McFarland, K.M. Clark, A.A. Morris, R.W. Taylor, S. Macphail, R.N. Lightowlers,
D.M. Turnbull, Nat. Genet. 30 (2002) 145–146.
[31] F.M. Santorelli, K. Tanji, M. Sano, S. Shanske, M. El-Shahawi, P. Kranz-Eble, S.
DiMauro, D.C. De Vivo, Ann. Neurol. 42 (1997) 256–260.
[32] R.W. Taylor, D.M. Turnbull, Nat. Rev. Genet. 6 (2005) 389–402.
[33] M. Zeviani, Suppl. Clin. Neurophysiol. 57 (2004) 304–312.
[34] S. Wortmann, R.J.T. Rodenburg, M. Huizing, F.J. Loupatty, T. de Koning, L.A.J.
Kluijtmans, U. Engelke, R. Wevers, J.A.M. Smeitink, E. Morava, Mol. Genet. Metab.
88 (2006) 47.
[35] Y. Zhang, Y.L. Yang, F. Sun, X. Cai, N. Qian, Y. Yuan, Z.X. Wang, Y. Qi, J.X. Xiao, X.Y.
Wang, Y.H. Zhang, Y.W. Jiang, J. Qin, X.R.Wu, J. InheritedMetab. Dis. 30 (2007) 265.
[36] M. Bohm, E. Pronicka, E. Karczmarewicz, M. Pronicki, D. Piekutowska-Abramczuk,
J. Sykut-Cegielska, H. Mierzewska, H. Hansikova, K. Vesela, M. Tesarova, H.
Houstkova, J. Houstek, J. Zeman, Pediatr. Res. 59 (2006) 21–26.
[37] L. Farina, L. Chiapparini, G. Uziel, M. Bugiani, M. Zeviani, M. Savoiardo, AJNR Am.
J. Neuroradiol. 23 (2002) 1095–1100.
[38] A. Merenda, R. Bullock, Curr. Opin. Crit. Care 12 (2006) 90–96.
[39] L. Sorensen, M. Ekstrand, J.P. Silva, E. Lindqvist, B. Xu, P. Rustin, L. Olson, N.G.
Larsson, J. Neurosci. 21 (2001) 8082–8090.
[40] C. Herrnstadt, J.L. Elson, E. Fahy, G. Preston, D.M. Turnbull, C. Anderson, S.S. Ghosh, J.
M. Olefsky,M.F. Beal, R.E. Davis, N. Howell, Am. J. Hum.Genet. 70 (2002) 1152–1171.
[41] D.D. de Vries, B.G. van Engelen, F.J. Gabreels, W. Ruitenbeek, B.A. van Oost, Ann.
Neurol. 34 (1993) 410–412.
[42] I.J. Holt, A.E. Harding, R.K. Petty, J.A. Morgan-Hughes, Am. J. Hum. Genet. 46 (1990)
428–433.
[43] N. Howell, R.J. Oostra, P.A. Bolhuis, L. Spruijt, L.A. Clarke, D.A. Mackey, G. Preston, C.
Herrnstadt, Am. J. Hum. Genet. 72 (2003) 1460–1469.
[44] K.K. Abu-Amero, T.M. Bosley, S. Bohlega, E. Hansen, Ophthalmic Genet. 26 (2005)
31–36.
[45] R.W. Taylor, R. Singh-Kler, C.M. Hayes, P.E. Smith, D.M. Turnbull, Ann. Neurol. 50
(2001) 104–107.
[46] C. Batandier, A. Picard, N. Tessier, J. Lunardi, Hum. Mutat. 16 (2000) 532.
[47] A.S. Jun, M.D. Brown, D.C. Wallace, Proc. Natl. Acad. Sci. U. S. A. 91 (1994)
6206–6210.
[48] A.L. Mitchell, J.L. Elson, N. Howell, R.W. Taylor, D.M. Turnbull, J. Med. Genet. 43
(2006) 175–179.
